Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2005
06/15/2005EP1541573A1 Novel crystals of triazaspiro 5.5 undecane derivative
06/15/2005EP1541571A1 Bicyclic unsaturated tertiary amine compound
06/15/2005EP1541570A1 Novel physiologically active substance
06/15/2005EP1541564A1 Five-membered heterocyclic compounds
06/15/2005EP1541563A1 Ccr4 antagonist and medicinal use thereof
06/15/2005EP1541560A1 Novel tetrahydroquinoline derivatives
06/15/2005EP1541559A1 5-substituted isoquinoline derivative
06/15/2005EP1541558A1 Heterocyclic compound having hiv integrase inhibitory activity
06/15/2005EP1541553A1 Novel indoline compound and medicinal use thereof
06/15/2005EP1541551A1 2-cyano-4-fluoropyrrolidine derivative or its salt
06/15/2005EP1541197A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
06/15/2005EP1541175A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
06/15/2005EP1541172A1 Remedy for intestinal diseases and visceral pain
06/15/2005EP1541171A1 Therapeutics for diabetes mellitus
06/15/2005EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
06/15/2005EP1541163A1 Hair growth stimulants for oral use
06/15/2005EP1541161A1 Tablet composition containing chinese orthodox medicine extract and process for producing the same
06/15/2005EP1541155A1 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation
06/15/2005EP1541151A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
06/15/2005EP1541149A1 Phosphodiesterase inhibitor
06/15/2005EP1541146A1 Zolpidem hemitartrate solvate
06/15/2005EP1541139A1 Drug composition containing nf-kappa b inhibitor
06/15/2005EP1541135A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof
06/15/2005EP1540332A1 Methods of screening compounds for grk6 modulating activity
06/15/2005EP1540012A2 Polymorphisms for predicting disease and treatment outcome
06/15/2005EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
06/15/2005EP1539957A1 Novel diagnostic and therapeutic methods and reagents therefor
06/15/2005EP1539942A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
06/15/2005EP1539931A1 Differentiation modulating agents and uses therefor
06/15/2005EP1539927A1 Probiotic bacterium: lactobacillus fermentum
06/15/2005EP1539802A2 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders
06/15/2005EP1539780A1 Derivatives of monosaccharides for drug discovery
06/15/2005EP1539779A2 Condensed palatinose in hydrogenated form
06/15/2005EP1539769A1 Bicyclic heteroaromatic compounds as kinase inhibitors
06/15/2005EP1539764A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
06/15/2005EP1539763A1 Azaindole kinase inhibitors
06/15/2005EP1539744A2 N-hydroxyamide derivatives possessing antibacterial activity
06/15/2005EP1539742A1 Indole derivatives useful as histamine h3 antagonists
06/15/2005EP1539740A1 Sulphonamide derivatives and their use as tace inhibitors
06/15/2005EP1539739A1 Piperidinyl compounds that selectively bind integrins
06/15/2005EP1539738A1 Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl]-piperidin-1-yl -methanone derivatives, methods for production and use thereof as medicaments
06/15/2005EP1539732A1 Novel compounds
06/15/2005EP1539730A1 Novel compunds, pharmaceutical compositions containing same, and methods of use for same
06/15/2005EP1539729A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
06/15/2005EP1539728A2 Fluorescent dyes, energy transfer couples and methods
06/15/2005EP1539727A2 Compounds, compositions, and methods
06/15/2005EP1539715A1 Crystal forms of quinoxaline-2-carboxylic acid 4-carbamoyl- 1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl -amide
06/15/2005EP1539714A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
06/15/2005EP1539701A1 Caspase inhibitors and uses thereof
06/15/2005EP1539699A1 4- 7'-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
06/15/2005EP1539695A1 N-4-piperidinyl compounds as ccr5 modulators
06/15/2005EP1539694A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity
06/15/2005EP1539693A1 Cannabinoid receptor agonists
06/15/2005EP1539689A2 Antisense modulation of endothelial lipase expression
06/15/2005EP1539685A1 Mcp-1 receptor antagonists and method of use thereof
06/15/2005EP1539683A2 Phenol derivatives and their use as rotamase inhibitors
06/15/2005EP1539679A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539674A1 Amino-propanol derivatives
06/15/2005EP1539662A1 Cannabinoid receptor ligands
06/15/2005EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
06/15/2005EP1539188A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
06/15/2005EP1539172A1 New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno[2,3-d]pyrimidine
06/15/2005EP1539169A2 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
06/15/2005EP1539166A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
06/15/2005EP1539165A1 Sustained-release tablet composition comprising a dopamine receptor agonist
06/15/2005EP1539164A1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
06/15/2005EP1539161A1 Novel salt and polymorphs of desloratadine hemifumarate
06/15/2005EP1539156A1 Liquid dosage forms of acid labile drugs
06/15/2005EP1539147A1 Methods of treating microbial infections in humans and animals
06/15/2005EP1539142A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer s disease
06/15/2005EP1539137A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539125A1 A composition comprising phytospingosine derivatives for apoptosis induction
06/15/2005EP1539120A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea
06/15/2005EP1538913A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/15/2005EP1538908A2 Novel substituted benzimidazole dosage forms and method of using same
06/15/2005EP1448560B1 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
06/15/2005EP1427842A4 Mid 9002, a human sulfatase family member and uses therefor
06/15/2005EP1419163B1 Tricyclic imidazopyridines
06/15/2005EP1408977B1 A combination therapy for the treatment of heart failure
06/15/2005EP1373240B1 Retinoid x receptor modulators
06/15/2005EP1368337B1 Piperazine derivatives and their use as 5-ht1b ligands
06/15/2005EP1349856B1 Isoindolin-1-one glucokinase activators
06/15/2005EP1345609B1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
06/15/2005EP1341764B1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
06/15/2005EP1325007B1 Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
06/15/2005EP1311259B1 Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent
06/15/2005EP1305301B1 Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
06/15/2005EP1276496B1 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
06/15/2005EP1251856B1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
06/15/2005EP1248836B1 Method for preparing vaccines by using hybrid cells
06/15/2005EP1248610B1 Use of at least a fatty ester for preparing a composition for the therapeutic and/or cosmetic treatment of prostatic hypertrophy, prostatic adenocarcinoma, acne, hyperseborrhea, alopecia and hirsutism
06/15/2005EP1244625B1 4-pyridinyl-n-acyl-l-phenylalanines
06/15/2005EP1198255A4 Identification of compounds that modify transcriptional responses to hypoxia
06/15/2005EP1171121B1 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth
06/15/2005EP1150973B1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
06/15/2005EP1126843A4 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
06/15/2005EP1114031B1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
06/15/2005EP1104412B1 Tace inhibitors
06/15/2005EP1075282B1 Peg-lhrh analog conjugates
06/15/2005EP1075270B1 Short peptide for treatment of neurological degenerative diseases
1 ... 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 ... 1564